The ECCO Pioneer Award was created to provide investigators with the support needed to explore new directions in IBD research. By encouraging visionary and interdisciplinary projects, the programme offers the opportunity to address questions that may ultimately change how we understand and approach IBD.
The GLYCANTALK project led by Salomé S. Pinho provides a compelling example of this ambition. Bringing together glycobiology, microbiome science and immunology, the project explored the relatively uncharted interface between the gut mucosal glycome, microbiota and immune response. By integrating experimental models with biological samples from patients with Crohn’s Disease and Ulcerative Colitis, the investigators identified an axis linking branched N-glycans, the microbiota and ILC3-mediated immune responses, providing new insights into the transition from intestinal homeostasis to inflammation.
Importantly, the project also moved beyond biological description. Experimental glycan supplementation was able to restore key microbial and immune signals and suppress intestinal inflammation, opening the possibility that modulation of mucosal glycosylation could eventually be explored as an interventional strategy. The project has already generated peer-reviewed publications, demonstrating how support can enable the translation of an original concept into tangible scientific output.
The GLYCANTALK experience illustrates why investment in pioneer research matters. Progress in IBD depends not only on refining established approaches, but also on giving researchers the opportunity to explore unexpected biological pathways that may reshape our understanding of disease and open new avenues for future research and treatment.
